Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate VaccineImmunotherapy for Recurrent Glioblastoma

Project: Research project

Project Details

Description

Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
StatusActive
Effective start/end date11/1/1810/30/25

Funding

  • OX2 THERAPEUTICS, INC.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.